DOI: 10.36347/sajb.2014.v02i09.015

Pages: 633-639

Ovarian cancer is most lethal of all the gynecological Cancer. The early stages of ovarian cancer are asymptomatic and more than 75% of the cases are diagnosed with regional or distant metastases. In present study our aim is to estimate the pre operatively serum level of CA-125, Salivary amylase and CEA in malignant and benign Epithelial ovarian cancer and their integrate use to predict malignant ovarian cancer. 50 malignant and 50 benign cases of epithelial ovarian cancer were included in this cross sectional study. Serum salivary amylase was estimated by SBio α AMYLASE (Direct Substrate Method) kit and CA-125 & CEA by electrochemi- luminescence immunoassay method. There was significant higher concentration of serum CA-125 and salivary amylase in malignant cases compare to benign cases of epithelial ovarian cancer (P<0.0001). Sensitivity and specificity of combine CA-125 and salivary amylase was 88% and 84% respectively. Concentration of CA-125 and salivary amylase was higher in advanced stage of ovarian cancer (p<0.05). Study concludes that Integrate use of CA-125 and salivary amylase can be used as marker to predict malignant ovarian cancer.